A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication LY3305677 against a placebo in adults who have obesity or are overweight to see how it affects body weight over 32 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 179 people

Who can join Ages 18–75 · all sexes

Timeline Started 2023-11 · est. completion 2025-07

Where 29 sites · United States

What this study is testing ClinicalTrials.gov NCT06124807 ↗

Description as written by the study sponsor.

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Treatments tested

Mazdutide also known as LY3305677 Drug

Administered subcutaneous (SC)
Placebo Drug

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight at Week 32
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight and Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06124807 ↗